Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Ceftolozane/tazobactam is an emerging newly available antibiotic that has a broad spectrum of
activity, and could be potentially useful in the management of central nervous system
infections. However, data relating to penetration of ceftolozane/ tazobactam into the central
nervous system, where a barrier against drug distribution exists (i.e. blood brain barrier),
is currently limited. In critically ill patients this is all the more challenging as
achieving adequate antibiotic concentrations even in blood is difficult.
The aim of this study is to describe the concentrations achieved in the cerebrospinal fluid
(i.e. bodily fluid found surrounding and inside of the brain) and blood after a single dose
of ceftolozane/tazobactam administered in critically ill patients with an existing external
ventricular drain (i.e. a device used in neurosurgery that relieves elevated intracranial
pressure in the brain). It is planned that this information gained will help develop dosing
strategies that will achieve target concentrations that will successfully treat central
nervous system infections in the future.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Royal Brisbane and Women's Hospital
Collaborator:
The University of Queensland
Treatments:
Ceftolozane Ceftolozane, tazobactam drug combination Cephalosporins Penicillanic Acid Tazobactam